Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib) – Eli Lilly and Company

1. Lilly’s Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)  Eli Lilly and Company
2. Targeted BTK Therapy Improves Survival in Untreated CLL/SLL  Physician’s Weekly
3. At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma  BioPharma Dive
4. FDA Approves Pirtobrutinib for Relapsed or Refractory Chronic Lymphocytic Leukemia  Pharmacy Times
5. Jaypirca shows promise as a frontline treatment for CLL/SLL patients | ASH 2025  Managed Healthcare Executive

Continue Reading